| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/12/2011 | CA2500649C Substituted arylhexadienoic acids and esters thereof, their use in the treatment of dyslipidaemia, diabetes and atherosclerosis, and processes for their preparation |
| 07/12/2011 | CA2500113C Therapeutic piperazine compounds |
| 07/12/2011 | CA2499756C Imidazopyrazines as cyclin dependent kinase inhibitors |
| 07/12/2011 | CA2499492C Methods of preparing cannabinoids from plant material |
| 07/12/2011 | CA2498275C Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders |
| 07/12/2011 | CA2495541C Wound dressing materials comprising complexes of anionic polysaccharides with silver |
| 07/12/2011 | CA2487672C Industrial process for preparing tropenol |
| 07/12/2011 | CA2481767C Severe sepsis preventive therapeutic agent |
| 07/12/2011 | CA2481268C Medicaments comprising steroids and a novel anticholinergic |
| 07/12/2011 | CA2480266C Use of an alpha2-adrenoreceptor antagonist for cns-related diseases |
| 07/12/2011 | CA2475704C Colonic release formulations of prednisolone sodium metasulphobenzoate coated with amylose, ethyl cellulose and dibutyl sebacate |
| 07/12/2011 | CA2470721C Superoxide dismutase mimics for the treatment of ocular disorders and diseases |
| 07/12/2011 | CA2470078C Selective urokinase inhibitors |
| 07/12/2011 | CA2467676C Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis |
| 07/12/2011 | CA2463505C Low-calcemic oxime analogs of 1.alpha.,25-dihydroxy vitamin d3 |
| 07/12/2011 | CA2461202C Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| 07/12/2011 | CA2458455C Pharmaceutical compositions comprising colloidal silicon dioxide |
| 07/12/2011 | CA2457528C Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina) |
| 07/12/2011 | CA2449150C Tricyclic compounds useful as angiotensin ii agonists |
| 07/12/2011 | CA2445341C Anthranilamides, process for their preparation, their use as antiarrhythmics, and pharmaceutical preparations thereof |
| 07/12/2011 | CA2441744C Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| 07/12/2011 | CA2435611C Alpha-amino-n-hydroxy-acetamide derivatives |
| 07/12/2011 | CA2431617C 7-heterocyclyl quinoline and thieno[2,3-b]pyridine derivatives useful as antagonists of gonadotropin releasing hormone |
| 07/12/2011 | CA2422617C Tripeptidyl peptidase inhibitors |
| 07/12/2011 | CA2421575C Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents |
| 07/12/2011 | CA2417858C Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| 07/12/2011 | CA2408956C Method and form of a drug delivery device,such as encapsulating a toxic core within a non-toxic region in an oral dosage form |
| 07/12/2011 | CA2406570C Dermal compositions containing coenzyme q as the active ingredient |
| 07/12/2011 | CA2393312C Aminobenzophenones as inhibitors of il-1.beta. and tnf-.alpha. |
| 07/12/2011 | CA2389685C Novel heterocyclic compounds and their use as medicaments |
| 07/12/2011 | CA2373972C Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations |
| 07/12/2011 | CA2351712C Crystal modification a of 8-cyano-1-cyclopropyl-7-(1s,6s-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid |
| 07/12/2011 | CA2341336C Elongase genes and uses thereof |
| 07/12/2011 | CA2312274C Isolated dna encoding human h3 histamine receptor |
| 07/12/2011 | CA2302874C Jnk3 modulators and methods of use |
| 07/12/2011 | CA2279971C Androgen synthesis inhibitors |
| 07/12/2011 | CA2220442C Chromatin regulator genes |
| 07/11/2011 | CA2786122A1 Nutritive compositions and methods of using same |
| 07/07/2011 | WO2011082426A1 Controlled release compositions comprising meclizine or related piperazine derivatives |
| 07/07/2011 | WO2011082409A2 Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
| 07/07/2011 | WO2011082400A2 Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| 07/07/2011 | WO2011082369A2 Injectable formulations for parenteral administration |
| 07/07/2011 | WO2011082368A2 Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
| 07/07/2011 | WO2011082355A1 Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| 07/07/2011 | WO2011082337A1 Therapeutic compounds and related methods of use |
| 07/07/2011 | WO2011082331A2 Compositions and methods for treating hepatitis b virus infection |
| 07/07/2011 | WO2011082290A2 Formulations from natural products, turmeric, and aspirin |
| 07/07/2011 | WO2011082283A2 Management of myoclonus with oral liposomal reduced glutathione |
| 07/07/2011 | WO2011082273A2 Substituted pyrrolo-aminopyrimidine compounds |
| 07/07/2011 | WO2011082267A2 Substituted triazolo-pyrazine compounds |
| 07/07/2011 | WO2011082266A2 Substituted heterocyclic compounds |
| 07/07/2011 | WO2011082245A2 Metalloenzyme inhibitor compounds |
| 07/07/2011 | WO2011082175A2 Glycosaminoglycan inhibitors |
| 07/07/2011 | WO2011082139A1 System for treating target ti s sue within the eustachian tube |
| 07/07/2011 | WO2011082111A1 Anaplerotic therapy for alzheimer's disease and the aging brain |
| 07/07/2011 | WO2011082098A1 Lysine and arginine methyltransferase inhibitors for treating cancer |
| 07/07/2011 | WO2011082081A1 Compositions including pyruvate for companion animals and methods of use thereof |
| 07/07/2011 | WO2011082080A1 Compositions including pyruvate for companion animals and methods of use thereof |
| 07/07/2011 | WO2011082077A1 Hepatitis c virus inhibitors |
| 07/07/2011 | WO2011082076A1 Amino acid conjugates of quetiapine, process for making and using the same |
| 07/07/2011 | WO2011082044A1 Topical lightening composition and uses thereof |
| 07/07/2011 | WO2011082010A1 Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia |
| 07/07/2011 | WO2011081971A2 Egfr/vegfr dual modulators and methods of using |
| 07/07/2011 | WO2011081970A2 MOLECULES RELATED hERG Ion CHANNELS AND THE USE THEREOF |
| 07/07/2011 | WO2011081942A1 Activation and activators of sirt5 |
| 07/07/2011 | WO2011081937A1 Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy |
| 07/07/2011 | WO2011081918A1 Hepatitis c virus inhibitors |
| 07/07/2011 | WO2011081915A2 Methods for treating erectile dysfunction in patients with insulin-dependent diabetes |
| 07/07/2011 | WO2011081861A2 Hair growth and / or regrowth compositions |
| 07/07/2011 | WO2011081698A1 Cgrp compositions and uses thereof |
| 07/07/2011 | WO2011081672A1 Low toxicity topical active agent delivery system |
| 07/07/2011 | WO2011081660A1 Nutritive compositions and methods of using same |
| 07/07/2011 | WO2011081628A1 Melt extruded nicotine thin strips |
| 07/07/2011 | WO2011081567A1 Agent for treating multiple sclerosis |
| 07/07/2011 | WO2011081556A1 Composition containing 6-decaprenyl-2,3-dimethoxy-5-methyl-1,4 -benzoquinone for parenteral delivery and method for producing same |
| 07/07/2011 | WO2011081509A1 Nutritional compositions comprising fruit flakes containing docosahexaenoic acid |
| 07/07/2011 | WO2011081493A2 Pharmaceutical composition comprising metformin and rosuvastatin |
| 07/07/2011 | WO2011081488A2 Composition for treatment of obesity using wheat bran extract or active ingredient isolated therefrom |
| 07/07/2011 | WO2011081445A2 Treatment use of ethylamino benzoic acid derivatives |
| 07/07/2011 | WO2011081430A2 Polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, preparation method thereof, and anticancer composition for combined use with radiotherapy |
| 07/07/2011 | WO2011081415A2 Sirna for inhibiting c-met expression and an anti-cancer composition comprising the same |
| 07/07/2011 | WO2011081408A2 Imatinib dichloroacetate and anti-cancer agent comprising the same |
| 07/07/2011 | WO2011081383A2 Composition including naphthoquinone compound for treating and preventing hearing loss |
| 07/07/2011 | WO2011081373A2 Method for preparing highly pure anhydrous crystalline docetaxel |
| 07/07/2011 | WO2011081253A1 Injectable porous microparticle filler system |
| 07/07/2011 | WO2011081229A1 Pharmaceutical composition for inhibiting angiogenesis |
| 07/07/2011 | WO2011081221A1 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction |
| 07/07/2011 | WO2011081205A1 1,3,4-oxadiazole-2-carboxamide compound |
| 07/07/2011 | WO2011081199A1 Oral preparation having improved quality |
| 07/07/2011 | WO2011081173A1 Tetracyclic compound |
| 07/07/2011 | WO2011081118A1 Pharmaceutical composition for oral administration |
| 07/07/2011 | WO2011081117A1 Solid pharmaceutical composition for oral administration |
| 07/07/2011 | WO2011081083A1 Neuraminic acid derivative, sialidase activity inhibitor and antiinfluenza drug |
| 07/07/2011 | WO2011080984A1 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction |
| 07/07/2011 | WO2011080982A1 Oil or fat composition for prevention or treatment of depression or depressed conditions |
| 07/07/2011 | WO2011080755A1 Fused nitrogen heterocyclic compounds, process of preparation and uses thereof |
| 07/07/2011 | WO2011080751A2 α4β2 NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS |
| 07/07/2011 | WO2011080740A1 Methods for enhancing natural killer cell proliferation and activity |
| 07/07/2011 | WO2011080739A2 Synergistic antibiotic combinations and derivatives |
| 07/07/2011 | WO2011080736A1 Intermediate compounds and processes for the preparation of tapentadol and related compounds |